secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021556
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics Q3 net loss $41.4M; Phase 1/2 trials for DM1 and DMD underway with data H2 2023
--------------------------------------------------------------------------------

- Net loss of $41.4M ($0.80 per share) vs $42.6M ($0.83) in Q3 2021; cash $248.1M funds operations through 2024.
- R&D expense $34.7M, G&A $7.6M; R&D slightly down YoY.
- ACHIEVE trial (DYNE-101 for DM1) and DELIVER trial (DYNE-251 for DMD) both enrolling; primary endpoints safety and tolerability.
- DYNE-251 granted FDA Fast Track designation in October 2022.
- Data from placebo-controlled portions of both trials anticipated in second half of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022021556/0000950170-22-021556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022021556/dyn-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer